Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Glycemia, triglycerides and disease severity are best associated with higher platelet activity in patients with stable coronary artery disease

  • 63 Accesses

  • 7 Citations



Inconsistent findings are reported about the relation of platelet activity to disease severity in stable patients with chronic coronary artery disease (CAD). Nevertheless, most reports studied only very small groups of patients. The purpose aim of our study was to assess the relation of platelet activity to disease severity in sufficient number of patients with chronic CAD.


One hundred and sixty stable patients with chronic CAD were studied (25 with single-, 63 with double- and 72 with triple-vessel disease). 91% of them were on aspirin, 1.6% on clopidogrel medication. Platelet activity was determined as membrane expression of antigens CD62P (P-selectin, as % of positive cells) and CD41 (part of GpIIb/IIIa integrin, as mean fluorescence intensity) by flow cytometry. Platelet aggregability was measured by ADP-optical aggregometry. Data sets were compared by Kruskal-Wallis test, correlation by Spearman test. Data are shown as median with 25–75 percentiles.


Membrane CD62P expression correlated with vessel severity (P < 0.001, Kruskal-Wallis test). Patients with triple-vessel disease had the highest CD62P expression (1.6; 1.1–2.0) followed by patients with double-vessel (1.2; 0.63–1.95) and single-vessel (0.7; 0.30–0.84) disease. Positive correlation was found between CD62P expression with triglycerides (r = 0.49, P < 0.05) and CD41 with fasting glucose (r = 0.48, P < 0.05). No differences in CD41 expression or ADP aggregability were found between groups.


Higher platelet activity is present in patients with more severe CAD. More aggressive anti-platelet treatment in these patients should be considered, especially when metabolic syndrome is simultaneously present.

This is a preview of subscription content, log in to check access.


  1. 1.

    Huo Y, Ley KF (2004) Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 14:18–22

  2. 2.

    Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD (2005) Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets 16:368–371

  3. 3.

    Ekmekci H, Isler I, Sonmez H et al (2006) Comparison of platelet fibronectin, ADP-induced platelet aggregation and serum total nitric oxide (NOx) levels in angiographically determined coronary artery disease. Thromb Res 117:249–254

  4. 4.

    Gawaz M, Neumann FJ, Schomig A (1999) Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 99:E1–E11

  5. 5.

    Michelson AD (2004) Platelet function testing in cardiovascular diseases. Circulation 110:e489–e493

  6. 6.

    Williams MS, Kickler TS, Vaidya D, Ng’alla LS, Bush DE (2006) Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis 21:241–247

  7. 7.

    Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N (2006) High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 133:315–322

  8. 8.

    Lim HS, Blann AD, Lip GY (2004) Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109:2524–2528

  9. 9.

    Bhatt DL, Fox KA, Hacke W et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717

Download references

Author information

Correspondence to Pavel P. Osmancik.

Additional information

The paper was supported by Charles University Prague Research Project No. MSM 0021620817 awarded by the Ministry of Education, Youth and Physical Education of the Czech Republic.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Osmancik, P.P., Bednar, F. & Móciková, H. Glycemia, triglycerides and disease severity are best associated with higher platelet activity in patients with stable coronary artery disease. J Thromb Thrombolysis 24, 105–107 (2007). https://doi.org/10.1007/s11239-006-9038-z

Download citation


  • P-selectin
  • Platelet
  • Coronary artery disease
  • Metabolic syndrome